A Cytokinetics heart disease drug — already approved in one indication — succeeded in another Phase 3 trial, a potential boost for sales.
Adobe
By Adam Feuerstein
May 5, 2026
Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and biotechnology.
Adam Feuerstein
Cytokinetics' Myqorzo's trial results, Johnson & Johnson's IBD therapy, and more biotech news from The Readout
Alzheimer's drug rollout letdown, a China-based heart drug startup, and more biotech news from The Readout
Regenxbio said its experimental gene therapy for Duchenne muscular dystrophy succeeded in a trial, paving the way for a…
The companies developing Ebvallo reached an agreement with the FDA to address its main reason for rejecting the drug.
Corvus Pharmaceuticals is developing an oral drug for a common skin condition that could push its shares a lot higher, according…
Some boys had astonishing recoveries. But other boys died. Now Astellas is returning to revised gene therapy for XLMTM.
